David W. Yesair received his Ph.D. from Cornell in 1958 and had worked in cutting-edge research and forefront technologies for over 40 years (22 years at Arthur D. Little, Inc. and as a vice president 5 years prior to founding BioMolecular Products, Inc. in 1984). He had more than 120 publications, including 11 book chapters, greater than 10 US and over 100 world patents. He had been selected for membership into 11 societies (including ASPET, SOT, AACR, ACS); received many honors (Sigma Xi, NIH and NSF fellowships); and was a charter member of the GRC drug metabolism, ISSX (International Society for the Study of Xenobiotics) and ILPS (International Lecithin and Phospholipid Society). His resumé can be found below.

Biomolecular Products, Inc. has had a large number of contracts with pharmaceutical companies, both large and small, government grants, memorandum of understanding with civic enterprises, etc. These sponsored, investigative studies answered many fundamental questions and provided insight about the mechanism of action, composition, etc. of Lym-X-Sorb™. The list of these companies, grants, etc. is listed alphabetically under "SPONSORS OF INVESTIGATIVE LYM-X-SORB™ STUDIES".

David Wayne Yesair, 1932-2007, Founder,
Inventor, and Developer of Lym-X-Sorb™

Education/Training:
Univ. Massachusetts, Amherst, MA: 1954, B.S. in Chemistry, Mathematics
Cornell University, Ithaca, NY: 1958, Ph.D. in Biochemistry, Organic Chemistry, Cellular Biology
Nat. Inst. Research, Shinfield, England: 1961/62, NSF Post-Doc. in Lipid Chemistry
CNRS, Natural Products, Gif s. Yvette (Paris), France: 1971/72, NCI Sabbatical, Structural studies on new macromolecular lipids of cell nuclei

A: Position and Honors:
Positions and employment:
1958 - 1962: Scientist, Lederle Laboratories of American Cyanamid (Isolation and characterization of peripheral nerve regeneration factor); 1961/62 (18 months) NSF Post Doctoral Fellow.
1962 - 1984: Arthur D. Little, Inc. (22 years)
1962 - 66: Senior Scientist, Biochemistry Group (Metabolism of antineoplastic and other drug classes).
1966 -77: Head, Biochemistry/Biochemical Pharmacology Group (Drug metabolism, pharmacokinetics, lipids, new product development); 1971-1972 (16 months) Sabbatical
1977 - 84: Vice President (New business development) and Leader, BioMolecular Science Section (Metabolism & Pharmacokinetics of xenobiotics in animals and humans)
1984 - pres.: Founder, President, BioMolecular Product, Inc., Lym-Med Nutritional Products, LLC. Lym- Drug Products, LLC and Lym-Derm Products, LLC (Develop and license lipid-based and patented LYM-X-SORB™ platform technology).

Other Experience and Professional membership:
Estimated Dates of Membership:
1957 American Chemical Society (ACS)
1966 American Association for the Advancement of Science (AAAS)
1966 Amer. Assoc. Cancer Research (AACR)
1967 Fellow of American Institute of Chemists (AIC)
1967 New York Academy of Science (NYAS)
1970 Amer. Soc. Toxicology (SOT)
1970 Amer. Soc. Pharmacology Experimental Therapeutics (ASPET)
1983 International Soc. Study Xenobiotics (ISSX, charter member, treasurer, secretary)
1985 International Lecithin & Phospholipid Society, (ILPS charter member)
1995 Northeastern Section of ACS (NESACS)
1997 American Oil Chemical Society (AOCS)

Honors:
1954-1958 National Institute of Health Pre-doctoral Fellowships
1958 Sigma Xi
1961 American Men of Science
1961-1962 National Science Foundation Post-doctoral Fellowship
1971 Leukemia Society of America Sabbatical Fellowship
1971-1972 National Cancer Institute sponsored sabbatical
1972-1982 Massachusetts Institute of Technology, guest lecturer (Pharmacokinetics of Drug and Xenobiotics) and doctoral research committee in the toxicology core curriculum
1975-1978 Member of National Cancer Institute Therapeutics Committee
1983 Chairperson of Gordon Research Metabolism Conference
1985-1987 Member of the University of Connecticut's Biotechnology Advisory Board
1988-1995 Monitor of Gordon Research Conferences
1992 Who's Who of American Inventors
1998 Who's Who in Science and Engineering
1999 Who's Who in the World
2nd Edition Who's Who in Frontiers of Science and Technology


B. Selected Publications:
(>40 peer-reviewed papers, including 11 book chapters and 11 US and >100 world patents)
Yesair, D.W., M. Callahan, L. Remington and C.J. Kensler. The role of the Enterohepatic cycle of Indomethin on its Metabolism, Distribution in Tissues and its Excretion by Rats, Dogs and Monkeys. Biochem. Pharmacol.1970,19:1579.

Yesair, D.W., F. J. Bullock and J.J. Coffey. The Pharmacodynamics of Drug Interaction, in Drug Metaboliam Reviews, F.J.Dicarlo (Ed.) Marcel Decker, New York, NY 1(1), 1972, p. 35.

Yesair, D.W., M.A. Asbell, R. Bruni, F.J. Bullock and E. Schwartzbach. Pharmacokinetics and Metabolism of Adriamycin and Daunomycin, in International Symposium on Adriamycin, Springer-Verlag, Heidelberg, 1972, p. 117

Yesair, D.W. and C.J. Kensler. The Phthalanilides, in Antineoplastic and Immunosuppressive Agents, Sartorelli and Johns (edc.), Handbuch der experimental Pharmcologie, Vol XXXVIII/2, Springer Verlag, New York, 1975, p.820.

Yesair, D.W., The Importance of Pharmacokinetic Principles in Characterizing Carcinogenic Thresholds for Naturally Occurring and Synthetics Chemical in Cancer and the Environment, Possible Mechanisms of Thresholds for Carcinogens and other Toxic Substances. J. Amer. College of Toxicology,1983, 2:55.

Yesair, D.W., A.B. Branfman and M.M. Callahan. Human Disposition and Some Biochemical Aspects of Methylxanthines in Methylxanthines Beverages and Foods, G. A. Spiller (Ed.) Alan Liss, Inc. NY ,NY, 1984, p. 215.

Yesair, D.W. Lipid Macromolecules as Chemotherapeutic Targets in Experimental and Clinical Progress in Cancer Chemotherapy, F. M. Muggia (Ed. ), Martinus Nijhoff Publishers, Boston, MA., 1985, p.13.

Yesair, D.W. Phosphatidylcholine and lysophosphatidylcholine in mixed lipid micelles as novel drug delivery systems, in 5th International Colloquium on Lecithin, I. Hanin and G. Pepeu (eds.), Plenum Publishin Corporation, New York, NY, 1990, p.83.

Lepage, G., D.W. Yesair, J. Champagne, N. Ronco, N. Bureau and C.C. Roy, Normalization of the absorption of lipids and of vitamin A from the matrix LYM-X-SORB™ with added retinyl palmitate in CF patients. Pediatric Pulmonology Supplement 19, 1999 Abstract 482.

Lepage, G., D.W. Yesair, J. Champagne, N. Ronco, N. Bureau, L. Lacombe, D. Bérubé and C.C. Roy, The Effect of PUFA-Enriched LYM-X-SORB™ on growth and lung function in CF patients with EFA deficiency. FASEB J. 1999; 13:A936.

Lepage, G., D.W. Yesair, N. Ronco, J. Champagne, N. Bureau, S. Chemtob, D. Bérubé and C.C. Roy, Effect of an Organized Lipid Matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis, The Journal of Pediatrics: 2002; 41 (2): 178. See editorial, p. 157.

Yesair, D.W. Lysophosphatidylcholine: A revolution in the Clinical Treatment of Cystic Fibrosis, 94th American Oil Chemist Society Annual Meeting, p. 97 (PHO 1 Symposium: Phospholipids for improving Bioavailability), 2003.


LYM-X-SORB™: US PATENTS AND PATENT APPLICATION:
4,874,795 Yesair, D.W. "Composition for delivery of orally administered drug and other substances." Expiration October 17, 2006.
5,314,921 Yesair, D.W. "Mixed lipid-bicarbonate colloidal particles." Expiration June 30, 2012.
5,571,517 Yesair, D.W. "Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories." Expiration May 24, 2015.
5,707,873 Yesair, D.W. "Method of assessing mixed lipid transport properties of drug." Expiration May 24, 2015.
5,716,814 Yesair, D.W. "Methods for making lysophosphatidylcholine." Expiration February 10, 2018.
5,741,822 Yesair, D.W. "Mixed lipid-bicarbonate colloidal particles for delivering Drugs." Expiration May 5, 2014.
5,891,466 Yesair, D.W. "Mixed lipid-bicarbonate colloidal particles for delivering drugs or calories." Expiration June 30, 2017.
5,972,911 Yesair, D.W. "Composition for delivery of orally administered drug and other substances." Expiration October 17, 2006.
6,426,069 Yesair, D.W. "Methods and compositions for increasing intestinal absorption of fats." Expiration September 7, 2019.
7,407,779 Yesair, D.W., W. A. Shaw, S. Burgess and T. McKee "Modification of solid 3-sn Phosphoglycerides." Expiration December 29, 2023


C. Completed Research Support:
1 R43 DK48208-01, Jun 1994 - Dec 1994
NIH/NIDDK
SBIR Phase I Grant "Carbon-13 Lipids, Oral Absorption in Cystic Fibrosis", PI
The goal of this study was to assess the readily absorbability of 13C- labeled organized lipid matrix versus 13C- labeled triglyceride in patients with CF and in the absence of enzyme supplement. The 13C- labeled LYM-X-SORB™ was readily absorbed being comparable to that observed in normal subjects. Triglyceride was minimally absorbed in patients with CF and in the absence of enzyme supplement.

1 R43 DK 60302-01, Mar 2002 - Dec 2002
HIH/NIDDK
SBIR Phase I Grant "Organized Lipid Matrix: Structural Integrity and Taste", co-PI.
Palatability enhancement of the organized lipid matrix was semonstrated as a function of complex head arrangement. Matrix protonization greatly improved the palatability profile via a proposed alteration in phase state. Sensory evaluation of the modified material as a component in butter cookies presented good results.

SPONSORS OF INVESTIGATIVE LYM-X-SORB™ STUDIES:
AVANTI POLARS LIPIDS, INC.
ASCENT PHARMACEUTICAL, INC.
AXCAN-PHARMA, INC.
BAYER AG
CENTRAL SOYA COMPANY, INC.
CHILDREN'S HOSPITAL OF LOS ANGELES
C. R. ASSOCIATES
FERNDALE LABORATORIES, INC.
GENZYME PHARMACEUTICAL, INC.
MARION LABORATORIES, INC.
McNEIL LABORATORIES
ORTHO PHARMACEUTICAL CORPORATION
SANDOZ CANADA INC.
SBIR PHASE I GRANT (NIH,NIDDK), "Carbon-13 Lipids, Oral Absorption in Cystic Fibrosis"
SBIR PHASE I GRANT (NIH,NIDDK), "Organized Lipid Matrix: Structural Integrity and Taste"
SAINTE JUSTINE HOSPITAL OF MONTREAL
THE UPJOHN COMPANY
U. S. ARMY NATICK LABORATORIES

This site was last updated on 11/30/05. Tatiana Harrison designed, created, and maintained this website. For more information about her webpage design, please click here.